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Abstract
Neonatal invasive disease caused by Group B Streptococcus (GBS) is responsible for
much acute mortality and long-term morbidity. To guide development of better prevention
strategies, including maternal vaccines that protect neonates against GBS, it is necessary
to estimate the burden of this condition globally and in different regions. Here, we present a
Bayesian model that estimates country-specific invasive GBS (iGBS) disease incidence in
children aged 0 to 6 days. The model combines different types of epidemiological data, each
of which has its own limitations: GBS colonization prevalence in pregnant women, risk of
iGBS disease in children born to GBS-colonized mothers and direct estimates of iGBS dis-
ease incidence where available. In our analysis, we present country-specific maternal GBS
colonization prevalence after adjustment for GBS detection assay used in epidemiological
studies. We then integrate these results with other epidemiological data and estimate coun-
try-level incidence of iGBS disease including in countries with no studies that directly esti-
mate incidence. We are able to simultaneously estimate two key epidemiological quantities:
the country-specific incidence of early-onset iGBS disease, and the risk of iGBS disease in
babies born to GBS-colonized women. Overall, we believe our method will contribute to a
more comprehensive quantification of the global burden of this disease, inform cost-effec-
tiveness assessments of potential maternal GBS vaccines and identify key areas where
data are necessary.
Author summary
Invasive disease caused by Group B Streptococcus (GBS) in young infants continues to be
a major public health problem in both developed and developing countries. However,
data on the incidence of this infection during the first week of life are only available for a
small number of countries, which has complicated the quantification of the burden of this
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disease globally. In this paper, we develop a Bayesian framework to estimate the incidence
of invasive GBS infection that combines data from multiple types of epidemiological stud-
ies, with adjustment for relevant factors such as diagnostic methods used in the studies.
We present estimates from a series of models, and our results highlight the potential weak-
nesses of different types of studies and the importance to consider the entire evidence
when estimating global burden of invasive neonatal infections. We believe this model is a
step toward better quantification of the number of cases in different regions.
Introduction
Infection by Group B Streptococcus (GBS), a gram-positive bacterium that colonizes the geni-
tal and gastrointestinal tracts [1,2], causes morbidity and mortality in babies in the first
months of life. With severe clinical manifestations that include sepsis and meningitis, invasive
GBS disease in infants aged a week or less is associated with case-fatality risks ranging from 5
to 27% [3]. However, despite its public health importance, until recently only a few studies had
tried to assess the global burden of this medical condition [4,5].
In the most comprehensive multi-country analysis to date, Seale and colleagues combined
data from different types of studies to estimate the global number of invasive GBS (iGBS) dis-
ease cases in babies [5]. In that analysis, knowledge on the pathogenesis of iGBS disease was
used to identify studies that provide relevant information: for example, colonization of the
genito-urinary tract of mothers by GBS is believed to be necessary, via a mechanism of in utero
infection or infection at delivery [6], for the development of iGBS disease in neonates aged a
week or less [7]. In addition to data on the percentages of mothers colonized by GBS, informa-
tion on the risk of early-onset, i.e. first 7 days of life, iGBS disease in infants born to GBS-colo-
nized mothers was also used. Combined, these data allowed the authors to estimate country-
specific numbers of early-onset iGBS disease cases. Studies that directly estimated the inci-
dence of early-onset iGBS disease among all live births, i.e. regardless of mothers’ GBS coloni-
zation statuses, were not used in these calculations but were compared to the estimates: direct
estimates of incidence from epidemiological studies were lower compared to estimates based
on maternal GBS colonization prevalence and data on risk in babies born to GBS-colonized
mothers. It was argued that under-estimation is common in incidence studies [5]. For exam-
ple, in an early study in the United Kingdom, authors estimated under-reporting of 44% and
21% from paediatricians and microbiologists, respectively, and that the number of cases might
have been ~20% higher than reported [8]. Consistent with this concern on case capture, a
recent study with prospective enhanced surveillance that captured data on iGBS disease in the
first 3 months of life using a variety of approaches found that for 53% of the identified cases
microbiological data from reference laboratories were not available [9]. As suggested in a
review of iGBS disease incidence studies performed in low and middle-income countries [4],
under-estimation could also be related to limited access to health care facilities and the fact
that a baby’s clinical condition might deteriorate rapidly, leading to fatal outcome before sam-
ples are collected. Indeed, in another review [3], the proportion of early-onset iGBS disease
cases diagnosed in the first 24 hours of life was higher in high income versus low income coun-
tries (74% and 31% respectively).
The use of maternal GBS colonization as predictor of early-onset iGBS disease also has its
own issues, including our limited understanding of the natural history of GBS in utero, vari-
ability in the risk of iGBS disease given maternal GBS colonization, as well as limited data on
coverage of intrapartum antibiotic prophylaxis (IAP), which affects this risk. To date, no study
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has integrated GBS colonization and direct iGBS disease incidence data, while adjusting for
variability in both datasets; this would require an evidence synthesis framework that combines
different data sources within a realistic model of iGBS disease natural history.
Quantification of incidence, and associated uncertainty, is the first step to estimate the
global burden of iGBS disease, including the burden linked to long-term consequences [10],
and is essential for priority setting around investment in preventive interventions such as GBS
vaccines [11,12] and roll out of antibiotic prophylaxis [13]. Here, we use Bayesian methods to
estimate the number of early-onset iGBS disease cases in countries with data on maternal GBS
colonization prevalence. We developed hierarchical models to estimate country-level maternal
GBS colonization prevalence and the risk of iGBS disease in babies born to GBS-colonized
women. Furthermore, in addition to data on GBS colonization and on risk of early-onset iGBS
disease in neonates of mothers with GBS colonization, we use data from incidence studies, i.e.
studies that estimate the percentage of newborns that develop early-onset iGBS disease regard-
less of maternal GBS colonization status. Hence, our model allows to synthesise evidence from
all these different sources. In the Results section, we first describe the different components of
the model separately, and then present results of the full model that combines these different
types of data.
Results
To estimate the number of cases of early-onset iGBS disease, we developed a Bayesian model
to combine data from different types of studies: (1) studies that estimated the prevalence of
GBS colonization during pregnancy; (2) studies that assessed the risk of early-onset iGBS dis-
ease in neonates born to GBS-colonized mothers in settings with different intrapartum antibi-
otic use; and (3) studies that estimated the incidence of early-onset iGBS disease in neonates
regardless of maternal GBS colonization status.
In the following subsections, the different components of the Bayesian model (Fig 1) are
described, including underlying assumptions and data. In the subsections GBS colonization
during pregnancy and Early-onset invasive GBS disease in babies born to GBS-colonized
Fig 1. The structures of the hierarchical model on maternal GBS colonization (left) and of the hierarchical model on
the risk of early-onset iGBS disease in babies born to colonized mothers (right) are shown. The component of the full
model that uses data on early-onset iGBS disease incidence as well as functions of parameters estimated in the two first
components is presented in the middle. Eqs 1 – 8 in the text describe model parameters and distributional
assumptions. Circles represent parameters; rectangles with single border, in the lower part of the figure, correspond to
observations and rectangles with double borders represent the hierarchical structure of the data.
https://doi.org/10.1371/journal.pcbi.1009001.g001
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mothers, hierarchical models are presented as independent analyses; and in the subsection Syn-
thesis with incidence data, the models described in the first two subsections are combined with
incidence studies.
GBS colonization during pregnancy
Since the pathogenesis of early-onset iGBS disease involves colonization of the maternal gen-
ito-urinary tract by GBS bacteria [2], determining the prevalence of maternal GBS coloniza-
tion informs the proportion of newborns at risk. In a recent systematic review, data from
studies reporting prevalence of GBS colonization during pregnancy were summarized; the
methods and inclusion criteria used in the review are described in detail elsewhere [14]. In
modelling GBS colonization prevalence, we use studies identified in that review.
Overall, data from 325 studies were included (Fig 2); 82 countries had at least one study to
inform country-level estimates of maternal GBS colonization prevalence. The number of stud-
ies per country ranged from 1 to 31, and the median number of participants in each study was
349 (range 35–17,430). The median prevalence of GBS in these studies was 14.6%.
These studies varied in two aspects that influence sensitivity of GBS detection [7]: the ana-
tomical sites from which samples were collected (vaginal sampling versus recto-vaginal sam-
pling) and the method used for microbiological diagnosis. Regarding the latter, microbiological
approaches were categorized in two for this analysis: selective agar (with or without enrichment)
and unselective agar (which has lower sensitivity). As shown in Fig A in S1 Appendix, these
factors influence prevalence estimates. In this analysis, 60% of the studies used the most sensi-
tive diagnostic combination (recto-vaginal sampling and selective agar for culture).
To estimate country-level GBS colonization prevalence in pregnant women, we developed a
Bayesian hierarchical model:





Fig 2. Data used in the hierarchical model of maternal GBS colonization. Study-specific percentages of mothers
colonized by GBS (circles) are presented (y-axis) by country (ISO3 codes are shown in the x-axis; arranged in order of
increasing median prevalence). Colors represent different combinations of microbiological methods and anatomical
sampling sites. Horizontal lines represent median maternal GBS colonization prevalence of the studies in each country.
The diameter of the circles is determined by the sample size in each study (see upper left corner of the figure).
https://doi.org/10.1371/journal.pcbi.1009001.g002
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where the logit-prevalence in a country j, μj, was assumed to be dependent on the logit-scale
global prevalence, μg, and standardized country-level variables, Xcj ; βc is a vector of country-
level regression coefficients. Between-country variation that is independent of covariates is
represented by the standard deviation σc. In this hierarchical model, prevalence pcolij in individ-
ual studies was modelled, on the logit scale, as a function of two binary variables (sampling site
and microbiological method); the intercept μj was the logit-prevalence in the country where
the study was performed. A common within-country between-study variance, s2s , is assumed.
The number of GBS-colonized pregnant women in study i performed in country j, ycolij , fol-
lowed a binomial distribution with parameters ncolij , the study sample size, and p
col
ij . βs represents
the vector of coefficients at the study level; and XSij, the vector of covariate values for study i in
country j.
The set of country-level variables used in this analysis was similar to that used in the previ-
ous review [5] and selected based on knowledge of the disease process (see Methods section for
a more detailed discussion on variables). To the covariates in the previous review [5], we
added country-level antibiotic coverage during respiratory infections in children, as a surro-
gate for antibiotic use that could influence GBS carriage. These variables were standardized,
i.e. the mean was subtracted, and the resulting value, divided by the standard deviation, before
inclusion in the model. The selection of country-level variables included in the final model is
described in the Methods section. Although Equs 1–3 present the centered parameterization of
this model, to minimize divergences observed in the estimation process, a non-centered
parameterization was used to sample the posterior distribution (see additional information in
the Methods section). Regression coefficients were assigned weakly informative normal priors,
Normal ~ (0, 1) and the parameter μg was assigned the prior Normal ~ (-1, 1), that corresponds
to the belief that the prevalence of GBS colonization in pregnant women is below 50%. Stan-
dard deviation parameters were assigned uniform priors, Uniform ~ (0, 5). Prior predictive dis-
tributions for the models presented in this and the following subsection (Figs B and C in S1
Appendix) and sensitivity analyses that used other prior assumptions are shown in the S1
Appendix.
Mixed predictive checks, as defined in [15,16] for hierarchical models, are presented in Fig
D in S1 Appendix. Posterior medians and 95% intervals of study- and country-level coeffi-
cients as well as standard deviation parameters are shown in Table 1. As expected, vaginal
sampling and use of less sensitive microbiological methods were associated with lower preva-
lence. For the following variables, there was evidence of association with GBS colonization
prevalence at the country-level: antibiotics coverage during respiratory infections, prevalence
of female obesity, gross national income per capita, neonatal mortality, and HIV prevalence.
In Fig 3, estimates (posterior medians and 95% intervals) of country-level prevalences are pre-
sented for the 82 countries with maternal GBS colonization data.
Early-onset invasive GBS disease in babies born to GBS-colonized mothers
Only a small percentage of babies born to GBS-colonized mothers develop iGBS disease, and
this risk is reduced by the administration of antibiotics during delivery, i.e. intrapartum antibi-
otic prophylaxis (IAP) [17]. Data to estimate the risk of early-onset iGBS disease come from
PLOS COMPUTATIONAL BIOLOGY Bayesian estimation of invasive GBS disease incidence
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Table 1. Maternal GBS colonization hierarchical model. Coefficients at the study and country levels and standard




Percent coverage of ATB for LRI 0.30 (0.07–0.53)
Maternal education -0.18 (-0.48–0.11)
GNI 0.16 (0.03–0.29)
Neonatal mortality 0.22 (0.00–0.44)
HIV prevalence 0.19 (0.06–0.32)
Obesity prevalence 0.20 (0.08–0.31)
Study-level covariates
Swab site -0.23 (-0.39 - -0.07)





Fig 3. Estimated maternal GBS colonization prevalence (y-axis) in countries (x-axis) with epidemiological data. Red circles represent studies that used sensitive GBS
detection protocols. Black circles represent posterior medians and lines, 95% intervals; these estimates correspond to country-level prevalences as quantified by sensitive
methods, i.e. inverse logit function of μj, and not to estimated prevalences in new GBS colonization studies, which would need to incorporate between-study variation and
sampling variation.
https://doi.org/10.1371/journal.pcbi.1009001.g003
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studies that were described in a review [18]; information on intrapartum antibiotic use was
reported in these studies. 9/28 studies were performed in the United States of America, and
14/28, in Europe. Sample sizes ranged from 216 to 3,819; and numbers of early-onset iGBS dis-
ease cases ranged from 0 to 24.
We analysed these data with the following hierarchical model:
ai � Normal ðag ; s
2
eoÞ ð4Þ
logit ðriÞ ¼ ai þ bIAPX
IAP
i ð5Þ
yeoi � Binomial ðri; n
eo
i Þ ð6Þ
where study-specific intercepts, αi, were assumed to be normally distributed with mean αg
and standard deviation σeo. The inverse logit of intercept αi represents the risk in the study
population i if IAP were not used; and βIAP is the coefficient of the association between
study-level antibiotic coverage (XIAPi ) and risk of early-onset iGBS disease. y
eo
i corresponds
to the number of early-onset GBS cases in study i and follows a binomial distribution with
parameters ri, the risk of early-onset iGBS disease in study i, and neoi , the sample size of
study i. The priors for αg, σeo and βIAP were Normal ~ (-4, 1), Uniform ~ (0, 5) and Normal
~ (0, 1), respectively (see also sensitivity analyses in S1 Appendix); the prior for αg reflects
the expected low risk of iGBS disease (< 10%). This model has lower widely applicable
information criterion (WAIC) [19] compared to a model with fixed intercept. We also fit a
model with an additional variable that categorized countries in two groups (North Amer-
ica and Europe, 23 studies; and Africa and Asia, 5 studies): no clear association between
this variable and risk of iGBS disease was observed; hence we only present results for the
model described in Eqs 4–6. Predictive checks for this model are shown in Fig E in S1
Appendix.
The posterior medians (95% intervals) of αg and βIAP are -4.12 (-4.92, -3.42) and -0.03
(-0.05, -0.02), respectively. Fig 4 shows the predicted risk (shaded areas) of early-onset iGBS
disease in new studies and the estimated risks in studies included in this analysis. Where IAP
is not used, the risk of early-onset iGBS disease in babies born to GBS-colonized mothers is on
average 1.6% (inverse logit of αg).
Synthesis with incidence data
In the analysis by Seale and colleagues [5], the incidence of early-onset iGBS disease was calcu-
lated by multiplying the estimated prevalence of GBS colonization in pregnant women and the
IAP coverage-adjusted risk of disease in babies born to colonized mothers. Data from studies
that directly estimated incidence were not used in the calculation, as it has been argued that
these studies under-estimate incidence, for example due to non-optimal access to care and
rapid fatality [3]. In this subsection, we combine the models presented in the two previous sub-
sections with data from incidence studies. In our primary analysis, we included only those
studies considered to be less biased (N = 10 studies) in a recent review [3]; in this subsection
we refer to this analysis as full model I. We also performed a secondary analysis that included
all incidence studies with relevant data (N = 30 studies) described in the same review; we refer
to this analysis as full model II. More information about these studies is presented in the Meth-
ods section.
PLOS COMPUTATIONAL BIOLOGY Bayesian estimation of invasive GBS disease incidence
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Fig 4. Risk of early-onset invasive GBS disease (EOGBS, y-axis) by intrapartum antibiotic coverage (x-axis). For this figure, the model described in the
subsection Early-onset invasive GBS disease in babies born to GBS-colonized mothers was used. The shaded area represents the 10–90% interval of the
risk of early-onset iGBS disease in a new study; the distribution was generated by assuming the intercept for a new study i follows the distribution
a
ðmÞ
i  new � NormalðaðmÞg ; s
ðmÞ
eo
2Þ, which uses estimates of αg and σeo at each iteration m. The darker orange shade represents the interquartile range of the
same distribution and the dashed line, the median. Of note, this does not incorporate the component of the predictive probability linked to sampling
uncertainty; it only incorporates the component related to estimation uncertainty. Each circle represents a different study included in the analysis, with
circles of similar colour corresponding to studies performed in the same country. Posterior medians and 95% intervals of the risk in these studies, i.e. ri
for studies in the analysis dataset, are shown as black lines.
https://doi.org/10.1371/journal.pcbi.1009001.g004
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Data from incidence studies were incorporated in the full model I, that combines Eqs 1–6,







ij Þ � g ð7Þ
yinci � Binomialðci; n
inc
i Þ ð8Þ
where yinci is the number of early-onset iGBS disease cases observed in the incidence study i;
ninci , the total number of births in the study population; p
0
ij is the predicted prevalence of mater-
nal GBS colonization in a study performed in country j, where the logit (p0ij) is assumed to be
normally distributed with parameters μj and σs; ci is the estimated study-specific probability of
early-onset iGBS disease, based on parameters defined in the previous subsections. Given that
incidence studies did not test pregnant women for GBS colonization, an assumption implied
in Eq 7 is that prevalence estimates as quantified by sensitive methods, in terms of culture
methodology and anatomical sampling site, represent the true underlying maternal GBS prev-
alence in these study populations. To allow for under-reporting (or under-ascertainment) of
cases, we introduced the parameter γ, that represents the proportion of all cases reported. In
the analysis that only included selected studies (full model I), this parameter was assumed to
be common for all incidence studies; we used as prior the distribution Beta ~ (2, 2) for γ. In the
secondary analysis that included a higher number of incidence studies (full model II), this
parameter was allowed to vary (see Methods section for details). We used α’i and βIAP to esti-
mate the risk of early-onset iGBS disease in babies born to colonized mothers in the incidence
study i population; α0i follows a Normal distribution with mean αg and standard deviation σeo.
XIAPij represents IAP coverage in the country j, assumed to correspond to the coverage in the
incidence study i population. This information was obtained from a study by Le Doare and
colleagues [20], who reviewed literature and consulted national medical societies to assess IAP
policy adoption. In this analysis, we did not differentiate between the prophylaxis approach
that involves treatment of pregnant women with evidence of GBS colonization and the
approach that uses risk factors to identify mothers who should receive antibiotics.
In the full model I, posterior medians and 95% intervals of the parameters estimated in the
subsection Early-onset invasive GBS disease in babies born to GBS-colonized mothers changed
to -4.17 (-4.69, -3.68) and -0.03 (-0.04, -0.02) for αg and βIAP, respectively. Estimates for these
same parameters in analyses using full model II were: -4.28 (-4.76, -3.79) and -0.02 (-0.03,
-0.017). Changes in coefficients relating country-level covariates and logit maternal GBS colo-
nization prevalence were minor after incorporating incidence data in the model (see Table A
in S1 Appendix). There were differences in posterior median GBS prevalences when compar-
ing the hierarchical GBS colonization model alone versus full models I and II (Fig F in S1
Appendix): as examples, after including data from incidence studies, the posterior median
maternal GBS colonization prevalence changed from 23.1 to 23.7% in Australia, 18.7 to 18.1%
in Malawi and 20.1 to 20.6% in the United Kingdom. The posterior median (95% interval) of
the parameter γ was 0.59 (0.34, 0.89) in the analysis that assumed the same parameter for all
incidence studies (full model I); using full model II, the following values (posterior medians
and 95% intervals) were estimated: 0.51 (0.28, 0.84), 0.38 (0.20, 0.69) and 0.67 (0.38, 0.93) for
population-based studies, facility-based studies in developing countries and facility-based
studies in developed countries, respectively. For comparison, Fig 5 shows the numbers of
early-onset iGBS disease cases estimated using the different models presented in this manu-
script for the 82 countries with maternal GBS colonization data.
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Discussion
We described a method to estimate country-level incidence of early-onset invasive GBS dis-
ease. This method uses studies previously reviewed in [5], where data on maternal GBS coloni-
zation were combined with results of epidemiological studies that estimate the risk of early-
onset iGBS disease in babies born to colonized mothers. For the estimation of country-level
maternal GBS colonization prevalence, we used a hierarchical model, which allowed partial
pooling of data from different countries and also allowed to directly account for between-
study differences in GBS detection methods. Furthermore, the method described here, unlike
the previous review (5), integrated indirect estimates, using data on the proportion of mothers
who are GBS colonized, with data from studies that directly estimate incidence of iGBS disease
in all live births.
In modelling maternal GBS colonization prevalence, we used a hierarchical model, which
has several advantages over standard regression methods [21], including partial pooling of
data and inclusion of predictors at different levels. At the study level, our model confirmed
and accounted for the association between microbiology diagnostics used in studies and
study-level prevalence. As one of the objectives in developing this model was to, in future anal-
yses, estimate GBS colonization prevalence in countries where no studies have been per-
formed, we also included country-level covariates in our model. The following variables were
associated with country-level maternal GBS colonization prevalence: HIV prevalence, antibiot-
ics use during lower respiratory infections (LRIs) in children, gross national income per capita,
neonatal mortality and obesity prevalence. At the individual level, HIV infection has been
linked to GBS infection phenotypes, although a recent meta-analysis suggests that HIV infec-
tion does not have a significant effect on maternal GBS carriage [22]. Antibiotics use during
LRIs, on the other hand, was included in our analysis as a surrogate for antibiotics availability
and use in different countries, which could influence frequencies of bacteria carriage, includ-
ing GBS. Our results suggest an association between this variable and maternal GBS coloniza-
tion prevalence at the national level, which should not be interpreted as causal at the
individual level [23,24] and could be related to other country-level differences in medical prac-
tices if this variable is not a close proxy for antibiotics use during pregnancy. Gross national
income per capita is likely associated with other factors that directly influence risk of
Fig 5. Estimated absolute numbers of early-onset invasive GBS disease cases (y-axis). Estimates for the 82 countries
(x-axis) with maternal GBS colonization data are shown. Black circles represent the number of cases estimated in the
evidence synthesis work by Seale and colleagues; uncertainty ranges reported by the authors are not Bayesian and not
included in this figure. Estimates from different models described here correspond to different colours: blue represents
Bayesian estimates that do not use incidence data; red represents full model I; and orange, full model II. For
comparability, we used the same numbers of live births per country as Seale and colleagues. See also Fig J in S1
Appendix for a similar comparison on the incidence scale.
https://doi.org/10.1371/journal.pcbi.1009001.g005
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colonization and could represent distal determinants of disease as defined by Victora and col-
leagues [25]. Furthermore, the association between obesity prevalence and country-level
maternal GBS colonization prevalence is supported by previous studies that demonstrate an
association at the individual level [26]. In future analyses, the posterior distributions of the
coefficients for these different variables will be used in the estimation of maternal GBS coloni-
zation prevalence for countries without data, which will also incorporate the unexplained
between country variation represented by the scale parameter σc. As seen in Table A in S1
Appendix, the inclusion of incidence data in our model did not modify country-level regres-
sion coefficients.
Studies that assessed the risk of early-onset iGBS disease in neonates born to GBS-colonized
mothers showed great variation in the proportion of children developing this medical condi-
tion, even when performed in the same country and with the same proportion of the study
population receiving antibiotics. This variability is shown in Fig 4. As expected, we observed
an association with study-level intrapartum antibiotic coverage, with studies with high cover-
age having an estimated risk below 1%. Pooled individual-level data analyses of these studies
might help to understand the heterogeneity in this risk and improve burden estimates.
Epidemiological studies that directly estimate iGBS disease incidence are believed to be
biased: for example, studies based on hospital data by design include children attending hospi-
tals with capacity to perform microbiological tests. In low- and middle-income countries, lim-
ited access to health care facilities might lead to a non-negligible proportion of cases being
missed when passive data capture is used. Another likely mechanism of under-estimation of
early-onset iGBS disease incidence relates to the sensitivity of microbiological methods. This
might apply to both incidence studies and studies that assess the risk of disease in babies born
to GBS-colonized mothers. Indeed, in a study performed in the United Kingdom, the esti-
mated combined incidence of confirmed and presumed early-onset iGBS disease was 3.6 cases
in 1,000 births [27], which is 6–7 times higher than the incidence estimated in a recent study
using prospective surveillance [9]; and in a review of incidence studies performed in develop-
ing countries, Dagnew and colleagues observed that studies with automated culture methods
for GBS detection had, on average, higher incidence of iGBS disease compared to studies with
manual culture methods [28]. Furthermore, in population-based studies, the comprehensive-
ness of the reporting from microbiology laboratories might be variable: in England and Wales,
increase in reporting was thought to partially explain longitudinal trends in iGBS disease inci-
dence [29]. Our model addresses this issue by integrating iGBS disease incidence data with
GBS colonization data and adjusting for under-reporting within an evidence synthesis frame-
work. Including data from incidence studies in our estimation led to changes in parameters of
the model, in particular those related to the risk of early-onset iGBS disease in babies born to
colonized mothers. Given our model assumptions, we estimated that incidence studies missed,
on average, ~40% of cases of iGBS disease that occurred in their study population. This is key
in the understanding of the burden of iGBS disease in infants, and there is an urgent need for
systematic data collection using different study designs, which can then be compared and inte-
grated within models such as the one we present. This will be crucial to the design of future
surveillance strategies for iGBS disease.
In summary, we developed a Bayesian model to estimate the national burden of early-onset
iGBS disease that combines different types of epidemiological data available on this important
neonatal condition. As shown in Fig 1, this allowed epidemiologically relevant parameters to
be informed by more than one study type. The efforts to develop a maternal vaccine that could
prevent GBS disease in neonates mean that estimations of the total burden of GBS disease are
essential to guide clinical development, trial design and policy adoption. Furthermore, these
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estimates could be used to inform decisions about IAP policy during a time when there is
heightened concern over antibiotic resistance.
Materials and methods
Data
Maternal GBS colonization and early-onset invasive GBS disease risk data. We used
data from two recent (2017) reviews [14,18]. Data on both maternal GBS colonization and cul-
ture-confirmed early-onset invasive GBS disease risk in children born to colonized mothers
were obtained from the supplementary appendices of these two manuscripts. For data on iGBS
disease risk given colonisation, we excluded from this analysis two of the 30 studies described
in the review by Russell et al that only included term neonates.
Data from incidence studies. In the review by Madrid and colleagues [3], studies with
data on the incidence of infant iGBS disease were selected that also reported a population
denominator (live births). In that analysis, 14 studies were considered less biased by the
authors and were selected for inclusion in our full model I. For two countries with two studies
among those considered less biased, we selected the most recent study for inclusion in our
analysis. Furthermore, two studies performed in countries without GBS colonization data
were not included. In two studies, authors reported corrected numbers of cases after account-
ing for study design; we used these corrected numbers in our estimation. In a secondary analy-
sis (full model II), we used all incidence studies reported in Madrid et al [3] that included data
from 0 to 6 days of life; as above, for countries with more than one incidence study, we
included the most recent.
Maternal GBS colonization model
Model parameterization. For the hierarchical model on maternal GBS colonization prev-
alence, we initially used a centered parameterization, as defined by Betancourt [30]. Since
divergences were frequently observed when sampling the posterior distribution (see Fig H in
S1 Appendix for an example of the distribution of the divergences in the parameter space
[31]), we re-parameterized the model using non-centered parameterization.
Study-level variables. In this hierarchical model, study-level variables were coded so that
high sensitivity methods were coded as 0, and low sensitivity methods, as 1, which allowed a
direct estimation of country-level prevalence based on sensitive diagnostics.
Country-level variables. Country-level variables were included in this analysis based on
the disease process and our knowledge of factors that could influence GBS carriage at the pop-
ulation level. To the list used in Seale et al [5], which includes variables that represent frequen-
cies of individual-level risk factors for GBS colonization, such as obesity and HIV infection,
variables that reflect access to care during pregnancy, such as skilled birth attendance coverage
and antenatal care coverage, and socio-economic variables (e.g. gross national income per cap-
ita, proportion of the population living in urban areas), we added antibiotics use for LRIs in
children, as it might represent general antibiotic availability that might influence GBS coloni-
zation prevalence. Data were obtained from relevant sources, including the World Health
Organization (neonates protected against tetanus, low-birth weight frequency, frequency of
cesarean section), the World Bank (gross national income per capita, GINI), the United
Nations (urbanization, neonatal mortality rates, fertility rates) and Institute for Health Metrics
and Evaluation (frequency of skilled birth attendance, age-standardized obesity prevalence,
years of maternal education, antibiotics coverage in lower respiratory infections, antenatal
care coverage). Missing values in country-level variables were input using the mean values in
each WHO region. Fig I in S1 Appendix presents the posterior distributions of the coefficients
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in the hierarchical model that included all the country-level variables. The final model
included the following variables, for which the 95% posterior interval did not include zero:
antibiotics coverage during LRIs, prevalence of female obesity, gross national income per cap-
ita and HIV prevalence. In addition, the variables neonatal mortality and maternal education,
whose coefficients had absolute median values ~0.2 and that are thought to be associated with
health care conditions during the neonatal period and maternal behavior that might influence
GBS colonization, respectively, were kept in the final model.
Additional analyses. We performed sensitivity analyses (see S1 Appendix for the list of
priors used in sensitivity analyses). Furthermore, in addition to the maternal GBS colonization
model presented in the Results section, we also fit a model with one additional hierarchical
level, WHO region-level. We compared the WAIC of the model presented in the Results sec-
tion and of this model that incorporated region-specific intercept terms in Eq 1; since the
WAIC values were similar, we decided to present the simpler model, without region-level.
MCMC algorithm
The models described in the Results section were fit to data using Hamiltonian Monte Carlo;
results were generated with PyMC3 and PyStan packages in Python; codes are available. Gel-
man-Rubin diagnostic was used to assess convergence.
Supporting information
S1 Appendix. In the S1 Appendix, we described sensitivity analyses and included addi-
tional figures and a table with results of model checks and comparisons. The following
tables and figures were included: Table A. Maternal GBS colonization regression coefficients
at the study and country levels and standard deviation parameters. Figure A. Study-specific
maternal GBS colonization prevalence (i.e. percentage of study population colonized by GBS
bacteria) by diagnostic combinations. Figure B. Maternal GBS colonization prevalence model
and prior predictive distribution. Figure C. Prior predictive distribution of the model on
early-onset invasive GBS disease in babies born to GBS-colonized mothers. Figure D. Mixed
predictive checks of the maternal GBS colonization prevalence model. Figure E. Mixed predic-
tive checks of the model on early-onset invasive GBS disease risk. Figure F. Posterior median
maternal GBS colonization prevalence estimated by the model that only used data from GBS
colonization studies and by the full model, that combined these data with early-onset iGBS dis-
ease incidence and risk data. Figure G. Predictive checks for the full model. Figure H. Distri-
bution of divergences in the centered model. Figure I. Posterior distributions of regression
coefficients in the hierarchical model for maternal GBS colonization that includes all variables.
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